The injectable drug delivery market encompasses a wide range of features, applications, and uses. Its key features include precise dosage control, targeted drug delivery, and rapid onset of action. Applications span various medical fields, including oncology, diabetes, cardiovascular diseases, and autoimmune disorders. Injectable drug delivery systems are used to administer medications, vaccines, and biologics directly into the bloodstream or specific body tissues. They offer benefits such as improved patient compliance, reduced side effects, and enhanced therapeutic outcomes, making them vital in modern healthcare for efficient and effective drug administration.
Access Full Report: https://www.databridgemarketresearch.com/reports/global-injectable-drug-delivery-market
Data Bridge Market Research analyses that the Global Injectable Drug Delivery Market is valued at USD 17.13 billion in 2021 and is expected to reach USD 46.84 billion by 2029, registering a CAGR of 13.40% during the forecast period of 2022 to 2029. Fiber optic gyroscopes find applications in industrial automation, robotics, and precision engineering. They enable precise control of robotic systems, improve accuracy in manufacturing processes, and enhance stability in industrial equipment which drives the market’s growth.
Key Findings of the Study
The increasing prevalence of chronic diseases is expected to drive the market's growth rate
The increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer, drives the growth of the healthcare market. Chronic diseases often require long-term treatment, including frequent medication administration. Injectable drug delivery systems provide a convenient and effective way to manage these conditions. The growing patient population with chronic diseases creates a higher demand for injectable drug delivery solutions, contributing to the overall market growth in the healthcare industry.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2022 to 2029
|
Base Year
|
2021
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
Segments Covered
|
Type (Injectable Drug Delivery Devices, Injectable Drug Delivery Formulation), Formulation Packaging (Ampoules, Vials, Cartridges, Bottles), Therapeutic Application (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Cancer, Others), Usage Pattern (Curative Care, Immunization, Other), Site Of Administration (Skin, Circulatory/Musculoskeletal System, Organs, Central Nervous System), Distribution Channel (Hospital, Retail Pharmacy Stores), End User (Hospitals and Clinics, Home Care Settings, Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
Market Players Covered
|
Abbott (U.S.), B.D. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Baxter (U.S.), Gerresheimer AG (Germany), AstraZeneca (U.K.), Terumo Medical Corporation (Japan), Teva Pharmaceutical Industries Ltd.(Jerusalem), Eli Lilly and Company (U.S.), Schott AG (Germany), Sanofi (France), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), West Pharmaceutical Services, Inc. (U.S.), SHL Medical AG (Switzerland), Insulet Corporation (U.S.), E3D Elcam Drug Delivery Devices (Israel), Ypsomed AG (Switzerland), AbbVie Inc. (U.S.), Novo Nordisk A/S (Denmark)
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The injectable drug delivery market is segmented on the basis of type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, and end user.
- On the basis of type, the injectable drug delivery market is segmented into injectable drug delivery devices and injectable drug delivery formulation. In 2022 the injectable drug delivery formulation market is expected to dominate at the highest CAGR of 11.5% in the forecasted period 2022 to 2029 as they help solubilize drugs that are not readily soluble or stable in their pure form, allowing for their effective delivery through injection.
In 2022, the injectable drug delivery formulation segment is dominating the type segment of the global injectable drug delivery market
In 2022, the injectable drug delivery formulation segment is dominating the market as formulations assist in preserving the stability of drugs by preventing degradation or chemical reactions, ensuring the medication's efficacy and shelf life. They allow for the combination of multiple drugs in a single injectable formulation, enabling the simultaneous administration of different medications for enhanced therapeutic outcomes.
- On the basis of formulation packaging, the injectable drug delivery market is segmented into ampoules, vials, cartridges, and bottles. In 2022 ampoules segment dominates injectable drug delivery as they help in maintaining accurate dosing and reduce the risk of contamination or wastage.
- On the basis of therapeutic application, the injectable drug delivery market is segmented into autoimmune diseases, hormonal disorders, orphan diseases, cancer, and others. In 2022, the hormonal disorders segment is expected to dominate the market with 50.1% market share as injectable drug delivery plays is widely used in the treatment of growth hormone deficiencies, especially in children.
- On the basis of usage pattern, the injectable drug delivery market is segmented into curative care, immunization and others. In 2022 the curative care is expected to dominate the market at the highest CAGR of 12.5% in the forecast period as injectable drug delivery allows for precise dosing, ensuring that the medication reaches the intended target and achieves the desired therapeutic effect.
- On the basis of site of administration, the injectable drug delivery market is segmented into skin, circulatory/musculoskeletal system, organs and central nervous system. In 2022, skin is the most common and the highest growing segment with the highest 12.8% CAGR in the forecast period as it plays crucial role in curative care by providing effective and targeted administration of medications to treat various diseases and conditions
In 2022, skin is dominating the site of administration of the global injectable drug delivery market
In 2022 skin segment is dominating the site of administration segment of the global injectable drug delivery market as injectable drug delivery systems designed for the skin, such as subcutaneous injections, offer convenience, patient acceptance, and self-administration capabilities. They are widely used for the treatment of chronic conditions like diabetes, autoimmune diseases, and hormonal disorders. The skin segment also plays a crucial role in delivering biologics and peptide therapies, providing targeted delivery, and offering long-acting formulations
- On the basis of distribution channel, the injectable drug delivery market is segmented into hospital and retail pharmacy stores. In 2022 hospital segment dominated the market due to the extensive use of injectable medications in hospital settings for various treatments, surgeries, emergency care, and critical conditions, ensuring accurate dosing and effective delivery of medications to patients.
- On the basis of end user, the injectable drug delivery market is segmented hospitals and clinics, home care settings and others. In 2022 hospital segment dominated the market as utilize a wide range of injectable medications for inpatient care, surgeries, emergency treatments, and critical conditions
Major Players
Data Bridge Market Research recognizes the following companies as the major injectable drug delivery market players in injectable drug delivery market are Abbott (U.S.), B.D. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Baxter (U.S.), Gerresheimer AG (Germany), AstraZeneca (U.K.)
Market Developments
- 2022年1月，West與康寧公司在藥物注射給藥領域達成重要合作。此次合作旨在利用康寧的Valor Glass技術來增強製藥業注射藥物的包裝和輸送系統。主要目標是提高患者安全性並擴大關鍵療法的可用性，確保更多患者能夠獲得挽救生命的治療。
- 2022年，碧迪公司推出了BD Ultrasafe Plus 2.25 ml被動針頭保護器，這是一款用於藥械組合產品的專用設備。透過將其與玻璃預灌封注射器配對，醫療保健專業人員可以安全地管理不同容量（最多 2 毫升）和黏度（最多 30 cP）的生物溶液。這項進步提供了一種可靠有效的藥物輸送方法，優先考慮患者安全並為醫療保健提供者提供值得信賴的解決方案。
- 2019 年 8 月，碧迪公司推出了 BD Ultrasafe Plus 2.25 毫升被動針頭保護器，這是一款專為藥物-設備組合產品設計的創新設備。與玻璃預灌封注射器一起使用時，該系統可使醫療保健專業人員安全地輸送不同體積（最多 2 毫升）和黏度（最多 30 cP）的生物溶液。這項進步確保了藥物的安全管理，將病患安全放在首位，並為醫療保健提供者提供了值得信賴的可靠解決方案。
- 2021 年 9 月，Antares Pharma, Inc. 啟動了 ATRS-1902 的 1 期研究，這是腎上腺危象救援的潛在解決方案。該研究重點評估該療法對成人和青少年急性腎上腺功能不全患者的療效。這種創新方法涉及利用專有的自動注射器平台來輸送液態氫化可的松。該計劃的目的是為經歷腎上腺危象的個人提供方便有效的治療選擇。
- 2021 年 11 月，碧迪公司推出了專為藥物器械組合產品設計的 BD Ultrasafe Plus 2.25 毫升被動針頭保護器。這種創新系統與玻璃預灌封注射器一起使用時，可以安全地註射容量高達 2ml、黏度高達 30 cP 的不同生物溶液。這項發展為醫療保健專業人員提供了一種可靠、高效的藥物輸送解決方案，同時確保了患者的安全。
區域分析
從地理上看，注射藥物輸送市場報告涵蓋的國家有：北美洲的美國、加拿大和墨西哥，歐洲的德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其，歐洲其他地區，中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓，亞太地區（APAC）的其他亞太地區（APAC），沙烏地阿拉伯、阿聯酋、南非、埃及、以色列，中東和非洲（MEA）的其他中東和非洲（MEA），巴西、阿根廷和南美洲的其他南美洲。
根據 Data Bridge 市場研究分析：
2022 年至 2029 年預測期內，北美是注射藥物傳輸市場的主導地區
2022 年，北美佔據了注射藥物輸送市場的主導地位，這歸因於先進注射藥物輸送系統的日益普及，而這種普及是由於對有效和有針對性的藥物管理的需求所驅動。大量患有慢性疾病且需要注射藥物的患者進一步促進了市場的成長。此外，醫療保健基礎設施和設施支出的增加提高了注射藥物傳輸系統的可近性和可用性，從而推動了該地區市場的擴張。
預計2022 年至 2029 年預測期內，亞太地區將成為注射藥物輸送市場成長最快的地區
2022 年，由於醫療保健專業人員和患者對注射藥物輸送系統益處的認識不斷提高，預計亞太地區將在預測期內實現成長。隨著認知的提高，人們越來越認識到精準劑量、有針對性的給藥和提高患者依從性等優勢。此外，由於慢性病盛行率的上升，該地區需要注射藥物的患者數量也不斷增加，促進了市場的擴張。
有關注射藥物輸送市場 報告的更多詳細信息，請點擊此處 - https://www.databridgemarketresearch.com/reports/global-injectable-drug-delivery-market
